Charis Segeritz-Walko

Charis Segeritz-Walko is an accomplished professional in the field of stem cell biology and drug development, currently serving as a Director at Novo Nordisk since August 2021, where responsibilities include advancing the company's cell therapy portfolio. Previously, Charis held the position of Principal Scientist at Novo Nordisk, focusing on bioengineering 3D in vitro tissues. At STEMCELL Technologies, Charis served as Team Lead and Senior Scientist, leading cross-functional teams and identifying new product opportunities in liver and pancreas research. Charis's earlier roles include consulting at GSK and DefiniGEN, and a strategy consultant position at Oxbridge Biotech Roundtable. Academic credentials include a Ph.D. in Stem Cell Biology from the University of Cambridge and both a Master’s and Bachelor’s degree from The University of British Columbia.